DOI: 10.36347/sjmcr.2024.v12i04.038

Pages: 539-541

Psychiatric disorders in Parkinson's disease can be classified into two opposing categories: hypodopaminergic if related to dopaminergic denervation and hyperdopaminergic if related to dopaminergic treatment. In this context the aim of this clinical case study is to present the psychiatric manifestations due to the use of a dopaminergic agonist anti parkinsonian (piribedil). We report the clinical case of a 55-year-old patient, hypertensive on Amlodipine, suffering from a parkinsonian disorder for 4 years; presenting to the psychiatric consultation at Ibn Nafis Hospital for a behavioural disorder following the introduction of Piribedil (antiparkinsonian dopaminergic agonist). Most of the psychic side effects of antiparkinsonian drugs are linked to their central dopaminergic properties. These effects are secondary to excessive stimulation of mesocorticolimbic dopamine receptors and/or serotonin hyperactivity.